Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2Sarcoma 1Other solid neoplasm 1Genitourinary 1Dermatologic 1

Conditions

Ovarian Neoplasms 171Fallopian Tube Neoplasms 85Uterine Cervical Neoplasms 40Carcinoma, Ovarian Epithelial 28Endometrial Neoplasms 27Neoplasms 14Peritoneal Neoplasms 10Colorectal Neoplasms 9Brenner Tumor 9Breast Neoplasms 9Stomach Neoplasms 8Recurrence 6Parkinson Disease 4, Autosomal Dominant Lewy Body 5Lung Neoplasms 5Carcinoma, Non-Small-Cell Lung 5Carcinoma 5Triple Negative Breast Neoplasms 4Pancreatic Neoplasms 4Carcinoma, Hepatocellular 4Squamous Cell Carcinoma of Head and Neck 3Prostatic Neoplasms 3Ovarian Diseases 3Melanoma 3Glioblastoma 3Carcinoma, Renal Cell 3Vulvar Neoplasms 2Vaginal Neoplasms 2Vaccinia 2Uterine Neoplasms 2Urinary Bladder Neoplasms 2

Interventions

Taxes 2Immunoglobulin G 2Disulfides 2Bevacizumab 2pembrolizumab 1Yoga 1Specimen Handling 1Sentinel Lymph Node Biopsy 1Salpingo-oophorectomy 1Radiation 1Platinum 1Paclitaxel 1Congresses as Topic 1Cisplatin 1Brachytherapy 1Albumin-Bound Paclitaxel 1130-nm albumin-bound paclitaxel 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Cervical Adenocarcinoma × Bevacizumab × Gynecologic × Clear all
NCT06543576 2025-08-15

External Beam Radiation Therapy and Brachytherapy With Chemotherapy and Immunotherapy for the Treatment of Stage IVB Cervical Cancer

Jonsson Comprehensive Cancer Center

Phase 1/2 Recruiting
35 enrolled
Gynecologic

Cervical Adenocarcinoma

NCT02020707 2024-07-26

Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers

Mayo Clinic

Phase 1 Completed
43 enrolled
DermatologicGenitourinaryGynecologicOther solid neoplasmSarcoma

Cervical Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡